TCE

Strategies for ADC and TCE in Treating Refractory Large B-Cell Lymphoma

by

1) The prognosis for refractory/relapsed LBCL not suitable for curative treatment is poor. The success of CD20×CD3 TCE mosunetuzumab combined with CD79b ADC polatuzumab vedotin in Phase 3 has provided patients with a novel, fixed-cycle, outpatient therapy. (Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial)In … Read more

Strange ADC Targets, Complex MoA, and Exhausted Bioassays

by
Strange ADC Targets, Complex MoA, and Exhausted Bioassays

When writing the previous article “TCE, Structure and Function, Bioassay Design,” I remained firmly in the “silent Fc” camp regarding TCE molecules. I wrote: For the new TCE molecules, it is generally preferred to choose a structural design with a silent Fc segment. By incorporating the Fc segment design, one can gain the advantage of … Read more